Thermo Fisher Scientific (TMO) Cost of Revenue (2009 - 2026)

Thermo Fisher Scientific (TMO) has 18 years of Cost of Revenue data on file, last reported at $3.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 4.35% year-over-year to $3.3 billion; the trailing twelve-month figure through Mar 2026 stood at $13.0 billion (up 1.66% YoY), and the FY2025 full-year result was $12.9 billion, up 2.05% from the prior year.
• Cost of Revenue for Q1 2026 stood at $3.3 billion, up from $3.2 billion in the prior quarter.
• Across five years, Cost of Revenue topped out at $3.7 billion in Q4 2023 and bottomed at $2.9 billion in Q4 2022.
• A 5-year average of $3.3 billion and a median of $3.2 billion in 2023 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue jumped 14305.0% in 2022 and slipped 9.06% in 2023, its largest moves.
• Tracing TMO's Cost of Revenue over 5 years: stood at $3.7 billion in 2022, then climbed by 1.39% to $3.7 billion in 2023, then declined by 7.18% to $3.5 billion in 2024, then declined by 6.78% to $3.2 billion in 2025, then climbed by 0.96% to $3.3 billion in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $3.3 billion, $3.2 billion, and $3.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison